Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.
Claims What is claimed is: 1. A method of reducing the plasma level of insulin-like growth factor-1 in an animal comprising: identifying an animal in need of a reduction in said animal's plasma level of insulin-like growth factor-1; and administering to said animal in need thereof a modified oligonucleotide 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleobases in length, wherein said modified oligonucleotide is fully complementary over the entirety of said modified oligonucleotide with a human growth hormone receptor RNA, wherein said modified oligonucleotide comprises at least one modified internucleoside linkage, modified sugar moiety, or modified nucleobase, and wherein the expression of growth hormone receptor in said animal is inhibited and said animal's plasma level of insulin-like growth factor-1 is reduced. 2. The method of claim 1, wherein said modified oligonucleotide is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleobases in length. 3. The method of claim 1, wherein said modified oligonucleotide is an antisense oligonucleotide. 4. The method of claim 1, wherein said modified oligonucleotide is a DNA oligonucleotide. 5. The method of claim 1, wherein said modified oligonucleotide is a RNA oligonucleotide. 6. The method of claim 1, wherein said modified oligonucleotide is a chimeric oligonucleotide. 7. The method of claim 1, wherein said modified oligonucleotide is a short interfering RNA molecule. 8. The method of claim 1, wherein said modified oligonucleotide comprises at least one 2'-O-(2-methoxyethyl) sugar moiety or a 4'-(CH2).sub.n--O-2' bridge, wherein n is 1 or 2. 9. The method of claim 1, wherein said modified oligonucleotide comprises at least one phosphorothioate internucleoside linkage. 10. The method of claim 1, wherein said modified oligonucleotide comprises at least one 5-methylcytosine. 11. The method of claim 1, wherein said modified oligonucleotide comprises: a region of deoxynucleotides flanked on the 5' and the 3' ends of said region with a 5' region and a 3' region, each of which 5' region and 3' region comprises at least one 2'-O-(2-methoxyethyl) nucleotide; wherein each internucleoside linkages of said modified oligonucleotide is a phosphorothioate internucleoside linkage; and wherein each cytosine of said modified oligonucleotide is a 5-methylcytosine. 12. The method of claim 11, wherein said modified oligonucleotide consists of 20 linked nucleosides. 13. The method of claim 1, wherein said modified oligonucleotide consists of a single-stranded modified oligonucleotide. 14. The method of claim 13, wherein the modified oligonucleotide consists of 20 linked nucleosides. 15. The method of claim 1, wherein said modified oligonucleotide comprises: a gap segment consisting of ten linked deoxynucleosides; a 5' wing segment consisting of five linked nucleosides; and a 3' wing segment consisting of five linked nucleosides; wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment comprises a 2'-O-methoxyethyl sugar; wherein each cytosine in said modified oligonucleotide is a 5-methylcytosine, and wherein each internucleoside linkage of said modified oligonucleotide is a phosphorothioate linkage. 16. The method of claim 15, wherein the modified oligonucleotide consists of 20 linked nucleosides. 17. The method of claim 1, wherein said animal is human. 18. A method of reducing the plasma level of insulin-like growth factor-1 in an animal comprising: administering to said animal a modified oligonucleotide 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleobases in length, wherein said modified oligonucleotide is fully complementary over the entirety of said modified oligonucleotide with a nucleic acid molecule having a sequence selected from the group consisting of SEQ ID NOs: 4 and 18, wherein said modified oligonucleotide comprises at least one modified internucleoside linkage, modified sugar moiety, or modified nucleobase, wherein the expression of growth hormone receptor in said animal is inhibited and said animal's plasma level of insulin-like growth factor-1 is reduced, and wherein said modified oligonucleotide comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 19, 22, 23, 24, 25, 28, 29, 30, 31, 32, 34, 35, 37, 40, 44, 45, 48, 51, 52, 54, 55, 56, 57, 58, 60, 61, 62, 63, 64, 66, 67, 68, 69, 71, 73, 74, 75, 76, 79, 81, 82, 84, 85, 87, 88, 89, 91, 92, and 94. 19. A method of reducing the plasma level of insulin-like growth factor-1 in an animal comprising: administering to said animal a modified oligonucleotide 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, or 26 nucleobases in length, wherein said modified oligonucleotide is fully complementary over the entirety of said modified oligonucleotide with a nucleic acid molecule having a sequence selected from the group consisting of SEQ ID NOs: 4 and 18, wherein said modified oligonucleotide comprises at least one modified internucleoside linkage, modified sugar moiety, or modified nucleobase, wherein the expression of growth hormone receptor in said animal is inhibited and said animal's plasma level of insulin-like growth factor-1 is reduced, and wherein said modified oligonucleotide is fully complementary to a nucleotide sequence within the range of nucleotides 332 to 351 of SEQ ID NO:4. 20. The method of claim 18, wherein said modified oligonucleotide consists of 20 linked nucleosides having a nucleobase sequence consisting of a nucleobase sequence recited in SEQ ID NO:19, wherein said modified oligonucleotide consists of a ten deoxynucleotide region flanked on both the 5' and 3' end of said ten deoxynucleotide region with five 2'-O-(2-methoxyethyl) nucleotides, wherein each internucleoside linkage in said modified oligonucleotide is a phosphorothioate linkage and each cytosine in said modified oligonucleotide is a 5-methylcytosine. 21. The method of claim 1, wherein the modified oligonucleotide consists of 20 linked nucleosides. 22. The method of claim 1, wherein said administration of said modified oligonucleotide is not intracranial. 